AVB-620

Avelas Biosciences, Inc. · Phase 2 active Small molecule

At a glance

Generic name	AVB-620
Also known as	Investigational Drug
Sponsor	Avelas Biosciences, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery (PHASE2)
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AVB-620 CI brief — competitive landscape report
AVB-620 updates RSS · CI watch RSS
Avelas Biosciences, Inc. portfolio CI